

Amendments to the Claims

Please replace the previously-pending claims with the following claim listing.

1. (Currently amended) A method of detecting a colon or lung cancer marker, the method comprising the steps of:

detecting an expression profile of at least one gene nucleic acid in a colon or lung cancer tissue from a human subject, wherein said at least one gene nucleic acid comprises a sequence is selected from the group consisting of NEK2, PLK1, ATR, and CHEK1 SEQ ID NO:1, SEQ ID NO:12, and SEQ ID NO:26;

comparing said expression profile to a normal tissue reference expression profile of said at least one nucleic acid; and

determining whether the nucleic acid is overexpressed compared to the normal tissue reference expression profile, thereby to detect a marker of the colon or lung cancer.

2-4. (Cancelled)

5. (Currently amended) The method of claim 21, wherein the biological sample is a colon sample, a lung sample, a breast sample, or a prostate sample, and said normal tissue reference expression profile is an average expression profile of said at least one gene nucleic acid in reference biological samples of cancer-free subjects.

6. (Currently amended) The method of claim 5, wherein said expression profile and said reference expression profile are determined using RT-PCR[,] or nucleic acid arrays, or immuneassays.

7. (Currently amended) The method of claim 1, wherein said subject has colon cancer, lung cancer, breast cancer, or prostate cancer.

8-25. (Cancelled)

26. (New) The method of claim 1, wherein said subject has lung cancer.

27. (New) The method of claim 1, wherein the sequence is SEQ ID NO:1.

28. (New) The method of claim 1, wherein the sequence is SEQ ID NO:12.

29. (New) The method of claim 1, wherein the sequence is SEQ ID NO:26.

30. (New) The method of claim 1, wherein the sequence is SEQ ID NO:31.